A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Trastuzumab
Related studies linked through entity extraction aliases.
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
MARGetuximab Or Trastuzumab (MARGOT)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
- Status
- RECRUITING
- Phase
- PHASE2
Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial
- Status
- COMPLETED
- Phase
- PHASE2
Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
- Status
- COMPLETED
- Phase
- NA
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
- Status
- UNKNOWN
- Phase
- PHASE2
Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.
- Status
- UNKNOWN
- Phase
- PHASE2
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A